Vimarsana
Biggest News Aggregation in the World

Underdiagnosed Form News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Underdiagnosed Form. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Underdiagnosed Form Today - Breaking & Trending Today

Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy - Vimarsana News

Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy

Published: February 8, 2024

CARLSBAD, Calif., Feb. 8, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has granted Fast Track designation to Ionis and AstraZeneca's...

Source: marketscreener.com
Related Topics:
Sarah WaltersEugene SchneiderIonis PharmaceuticalsDrug AdministrationIonis Pharmaceuticals IncColumbia University Irving Medical CenterFast TrackOrphan Drug DesignationTransthyretin Mediated Amyloid CardiomyopathyConjugated AntisenseSerum VitaminRecommended SupplementationPrescribing InformationUniversity Irving Medical CenterDrug Reduces DeathUnderdiagnosed FormHeart Failure
AstraZeneca's Wainua receives FDA approval in the US - Vimarsana News

AstraZeneca's Wainua receives FDA approval in the US

Published: December 22, 2023

AstraZeneca's Wainua receives FDA approval in the US

Source: directorstalkinterviews.com
Related Topics:
United StatesIsabelle LousadaMichaelj PolydefkisColumbia University Irving Medical CenterEuropean ParliamentDrug AdministrationJournal Of The American Medical AssociationCommission Implementing DecisionAmyloidosis Research ConsortiumIonis PharmaceuticalsEuropean CommissionNeuropathy Impairment ScoreNorfolk QualityLife Questionnaire Diabetic NeuropathyAmerican Medical AssociationJohns Hopkins University SchoolExecutive Vice PresidentBiopharmaceuticals Business UnitLatin AmericaOrphan Drug DesignationHereditary Transthyretin Amyloidosis WithAnnual ReportClin RiskGlobal PhaseAntisense Oligonucleotide
AstraZeneca : Wainua (eplontersen) granted first-ever regulatory approval in the US for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis - Form 6-K -December 22, 2023 at 06:21 am EST - Vimarsana News

AstraZeneca : Wainua (eplontersen) granted first-ever regulatory approval in the US for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis - Form 6-K -December 22, 2023 at 06:21 am EST

Published: December 22, 2023

A7568x FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Issuer Pursuant to Rule 13a-16 or...

Source: marketscreener.com
Related Topics:
United KingdomUnited StatesIoni WainuaIsabelle LousadaMichaelj PolydefkisAdrian KempInvestor Relations TeamAmyloidosis Research ConsortiumColumbia University Irving Medical CenterDrug AdministrationEuropean CommissionCompany SecretarySecurities ExchangeIonis PharmaceuticalsCommission File NumberJournal Of The American Medical AssociationEuropean ParliamentCommission Implementing DecisionForeign IssuerSecurities Exchange ActFile NumberCrick AvenueRegulationst RuleNeuropathy Impairment ScoreNorfolk Quality
NEURO-TTRansform Phase III results presented at AAN showed eplontersen demonstrated consistent and sustained improvement in all measures of disease and quality of life through 66 weeks - Vimarsana News

NEURO-TTRansform Phase III results presented at AAN showed eplontersen demonstrated consistent and sustained improvement in all measures of disease and quality of life through 66 weeks

Published: April 24, 2023

Eplontersen halted neuropathy disease progression and improved neuropathy impairment and quality of life ... | June 18, 2023

Source: marketscreener.com
Related Topics:
United StatesUnited KingdomAmerican Academy Of NeurologyColumbia University Irving Medical CenterDrug AdministrationIonis PharmaceuticalsEmerging Science SessionAmerican AcademyNew Drug ApplicationOrphan Drug DesignationRare DiseasesNeurol NeurosurgUniversity Irving Medical CenterDrug Reduces DeathUnderdiagnosed FormHeart FailureAnnual ReportGlobal PhaseAntisense OligonucleotideOpen Label PhaseNeurol Ther
Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks - Vimarsana News

Eplontersen demonstrated sustained benefit in Phase III trial for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) through 66 weeks

Published: March 27, 2023

Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy showed eplontersen met its co-primary endpoints... | March 27, 2023

Source: marketscreener.com
Related Topics:
United KingdomUnited StatesEugene SchneiderSami KhellaPenn Presbyterian Medical CenterDrug AdministrationIonis PharmaceuticalsColumbia University Irving Medical CenterClinical DevelopmentUniversity Of Pennsylvania School MedicineAmerican Academy Of Neurology Annual MeetingDepartment Of NeurologyNeuropathy Impairment ScoreNorfolk QualityLife Questionnaire Diabetic NeuropathyClinical NeurologyPennsylvania SchoolExecutive Vice PresidentChief Clinical Development OfficerAmerican AcademyNeurology Annual MeetingNew Drug ApplicationOrphan Drug DesignationEmerging ScienceRare Diseases